CPIC emphasizes quality growth and disciplined ALM as NBV growth moderates from a high base

Overview

This conference takeaway summarizes CPIC management’s views on life-insurance NBV growth, investment allocation and P&C underwriting. Goldman Sachs highlights continued quality-focused growth and disciplined asset-liability management while retaining Buy on the H shares and Neutral on the A shares.

Core views

At the Asia Leaders Conference, CPIC management said NBV growth is likely to moderate after three years of strong expansion, during which NBV grew at a 26% CAGR. Management attributed part of that growth to broader industry momentum, but emphasized that CPIC’s own quality-growth strategy has supported margin expansion through product-mix shifts, pricing changes and lower channel expenses. It believes the company remains positioned for balanced growth because of its balanced channel and product offering. On investments, management reaffirmed a core strategy intended to balance dividend yield with long-term capital gains. CPIC’s equity allocation, including stocks and equity funds, increased by 2.7 percentage points to 13.9% in 1H26 from 11.2% in FY24. Management said there remains room to increase equity exposure, but any increase should remain aligned with asset-liability management (ALM) and strategic asset allocation (SAA) requirements. Its focus is net investment return, and it considers the current allocation sufficient to achieve a 4% total investment-return target. Management also stressed disciplined ALM. CPIC Life remains comfortably above regulatory requirements under new ALM guidelines, according to management. It expects C-ROSS Phase III, likely to be implemented by early 2027, to provide additional flexibility to optimize strategic asset allocation. For P&C operations, management sees limited room for further auto-insurance premium-rate declines because rates are already approaching the regulator’s target risk premium. Catastrophe claims year to date are higher than in 2025, although reinsurance could partly offset the effect. Management sees the claims pattern as similar to 2024 and is focused on improving risk-mitigation measures to reduce catastrophe-loss impacts. Goldman Sachs rates CPIC H/A shares Buy/Neutral. Its 12-month SOTP-based targets are HK$37.0 for 2601.HK and Rmb38.0 for 601601.SH, implying 0.8x and 1.0x FY27E P/B, respectively. The valuation assigns CPIC Life 1.1x/1.3x FY27E P/B based on Goldman Sachs’ ROA projection, and CPIC P&C 1.1x/1.2x FY27E P/B based on FY27E ROE of 12.8%.

Analysis framework

Goldman Sachs synthesizes management comments from the conference across NBV growth, product and channel economics, investment allocation, ALM, and P&C underwriting. It then values the life and P&C businesses separately using FY27E price-to-book multiples and combines them in a sum-of-the-parts valuation.

Methodology notes

• Valuation methodsSOTP (Sum-of-the-Parts) Valuation

  Sum-of-the-parts valuation

  Goldman Sachs values CPIC Life and CPIC P&C separately using FY27E P/B multiples, then combines the values into group target prices.

• Other

  Asset-liability management (ALM) and strategic asset allocation (SAA)

  Management assesses equity-allocation increases against liability needs and strategic allocation limits while targeting a 4% total investment return.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• China Pacific Insurance (H) (2601.HK)

  Covered H-share security rated Buy by Goldman Sachs.

  Strengths

  Quality-led NBV margin expansion, balanced channels and products, and disciplined investment strategy.

  Weaknesses

  NBV growth is expected to moderate from a high base.

  Comparison

  Target price of HK$37.0 implies 0.8x FY27E P/B.

  Risks

  Agent-headcount growth, P&C competition, dividend payout, and long-term bond yields could affect outcomes.

• China Pacific Insurance (A) (601601.SH)

  Covered A-share security rated Neutral by Goldman Sachs.

  Strengths

  Same group-level quality-growth and ALM strategy.

  Weaknesses

  NBV growth is expected to moderate from a high base.

  Comparison

  Target price of Rmb38.0 implies 1.0x FY27E P/B.

  Risks

  Agent-headcount growth, P&C competition, dividend payout, and long-term bond yields could affect outcomes.

Key data

• NBV growth CAGR26%Over the last three years; management expects growth to moderate from a high base.
• Equity allocation13.9%In 1H26, up 2.7 percentage points from 11.2% in FY24.
• Total investment-return target4%Management considers the current asset allocation sufficient to meet this target.
• H-share price target and upsideHK$37.00; 21.2%12-month target for 2601.HK versus HK$30.52 as of 2 September 2026 close.
• A-share price target and upsideRmb38.00; 15.7%12-month target for 601601.SH versus Rmb32.83 as of 2 September 2026 close.
• FY27E P&C ROE12.8%Used to support Goldman Sachs’ P&C valuation multiple.

Impact & implications

The report presents margin expansion, balanced distribution and product mix, and disciplined ALM as the basis for CPIC’s value-creation strategy even as headline NBV growth slows. It also indicates that C-ROSS Phase III could broaden allocation flexibility, while P&C results remain sensitive to catastrophe claims and competitive underwriting conditions.

Risks

• Core agent headcount may fail to grow, resulting in average or below-average NBV growth versus leading peers.
• Competition from medium-sized competitors could increase P&C underwriting losses.
• A higher savings-product mix and capital consumption at CPIC Life could lower the dividend payout ratio.
• Further declines in long-term government-bond yields could pressure investment returns and long-term product profitability.